Trials / Withdrawn
WithdrawnNCT01543139
Cytidine- and Creatine-Containing Drug in Treating Bipolar Depression
A Double-Blind, Placebo-Controlled Trial of Combined Cytidine- and Creatine-Containing Drug and Dietary Supplement in the Treatment of the Bipolar Depression
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Ewha Womans University · Academic / Other
- Sex
- All
- Age
- 19 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This proposed research is aimed to investigate the efficacy and safety of combined cytidine- and creatine-containing drug and dietary supplement in treating bipolar depression and to evaluate changes in relevant brain biochemical metabolism using magnetic resonance spectroscopy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Valproate+Cytidine-+Creatine- | Valproate: Week0-8: 300mg/day, Cytidine-: Week0-8: 2g/day, Creatine-: Week0-1: 3g/day Week1-8: 5g/day |
| DRUG | Valproate+Cytidine- | Valproate: Week0-8: 300mg/day, Cytidine-: Week0-8: 2g/day |
| DRUG | Valproate | Valproate: Week0-8: 300mg/day |
Timeline
- Start date
- 2015-12-01
- Primary completion
- 2017-04-30
- Completion
- 2017-04-30
- First posted
- 2012-03-02
- Last updated
- 2018-02-09
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01543139. Inclusion in this directory is not an endorsement.